Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Temazepam
Drug ID BADD_D02148
Description Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chemical synthesis of temazepam was established by 1965 [A175333], mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted and approved later on. In particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to obtain the necessary rest required for medical recovery or scheduled maneuvers and operations [A175339]. Regardless, temazepam has become one of the most frequently prescribed medications internationally and sees millions of prescriptions every year. Unfortunately, however, given its frequent use and the inherent nature of its pharmacological effects, temazepam - like many other benzodiazepines - possesses a high potential for misuse and is genuinely capable of developing drug tolerance, physical dependence, and addiction in users.
Indications and Usage For the short-term treatment of insomnia (generally 7-10 days).
Marketing Status Prescription; Discontinued
ATC Code N05CD07
DrugBank ID DB00231
KEGG ID D00370
MeSH ID D013693
PubChem ID 5391
TTD Drug ID D04BNP
NDC Product Code 35356-821; 46708-380; 71610-625; 71335-1901; 71205-914; 63629-1054; 63629-1621; 17856-0148; 12828-0022; 65162-556; 61919-438; 46708-379; 53489-649; 63187-718; 55289-660; 70518-2926; 60429-507; 62332-381; 65162-557; 71610-101; 71335-0527; 43353-312; 60760-959; 70518-3093; 63629-8604; 67877-146; 70518-3057; 63187-132; 71610-626; 43547-613; 62332-382; 64330-088; 67877-149; 53489-651; 71335-0315; 55289-196; 67877-148; 63629-8603; 43547-611; 43353-260; 71610-004; 0406-9915; 71610-262; 0406-9960; 43547-612; 0904-6436; 63629-8605; 63629-8602; 62332-379; 68788-7163; 50090-0186; 68788-6986; 50090-0285; 62332-380; 0406-9917; 71610-089; 68084-549; 70518-3229; 65162-584; 70518-2487; 50090-3563; 0406-9962; 35356-664; 68071-2581; 53489-650; 0406-9916; 53489-648; 67544-136; 65162-583; 43353-152; 63629-1619; 46708-381; 0406-9961; 70518-3227; 61919-214; 71205-915; 46708-382; 65015-746; 0406-9914; 43547-614; 66267-321; 71335-2043; 48087-0045; 42291-797; 68788-8081; 63629-8601; 60429-506; 0228-2077; 0406-9959; 71610-086; 67877-147; 35356-663; 63629-8606; 68788-8139; 63187-497; 70518-2008; 0228-2076; 48087-0016; 63739-003; 61919-264; 63629-1057
Synonyms Temazepam | Hydroxydiazepam | Oxydiazepam | 3-Hydroxydiazepam | 3 Hydroxydiazepam | Methyloxazepam | Planum | PMS-Temazepam | PMS Temazepam | Pronervon T | Remestan | Restoril | Ro-5-5345 | Ro 5 5345 | Ro55345 | SaH 47-603 | SaH 47 603 | SaH 47603 | Signopam | Temaze | Temazep Von Ct | Von Ct, Temazep | Tenox | WY-3917 | WY 3917 | WY3917 | Apo-Temazepam | Apo Temazepam | Dasuen | Euhypnos | Gen-Temazepam | Gen Temazepam | Levanxol | Norkotral Tema | Tema, Norkotral | Normison | Temtabs | Nocturne | Normitab | Nortem | Novo-Temazepam | Novo Temazepam | Nu-Temazepam | Nu Temazepam
Chemical Information
Molecular Formula C16H13ClN2O2
CAS Registry Number 846-50-4
SMILES CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sleep apnoea syndrome22.02.01.013; 19.02.05.002; 17.15.05.001--
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.0040.000510%
Syncope02.01.02.008; 24.06.02.012; 17.02.04.0080.000510%
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thinking abnormal19.10.03.001; 17.02.05.0230.000510%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tremor17.01.06.0020.000510%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Withdrawal syndrome19.07.02.005; 08.06.02.0120.001276%Not Available
Paradoxical drug reaction08.06.01.014--Not Available
Muscle tightness15.05.03.0070.000510%Not Available
Balance disorder17.02.02.007--Not Available
Protein urine present13.13.02.006--Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.001--Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000510%
Blood alkaline phosphatase increased13.04.02.004--
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Obstructive airways disorder22.03.01.011--Not Available
Pulmonary function test decreased13.19.01.001--Not Available
Treatment failure08.06.01.0170.000133%Not Available
Device stimulation issue27.01.02.005--Not Available
Gastrointestinal tract irritation07.08.03.008--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages